Divalproex Sodium Patent Expiration
Divalproex Sodium is Used for managing and preventing seizures in epilepsy and sometimes used for treating migraine headaches. It was first introduced by Abbvie Inc
Divalproex Sodium Patents
Given below is the list of patents protecting Divalproex Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Depakote Er |
US6419953 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er |
US6511678 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er |
US6528090 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er |
US6528091 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er |
US6713086 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er |
US6720004 (Pediatric) | Controlled release formulation of divalproex sodium |
Jun 18, 2019
(Expired) | Abbvie |
| Depakote Er | US6419953 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
| Depakote Er | US6511678 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
| Depakote Er | US6528090 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
| Depakote Er | US6528091 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
| Depakote Er | US6713086 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
| Depakote Er | US6720004 | Controlled release formulation of divalproex sodium |
Dec 18, 2018
(Expired) | Abbvie |
Divalproex Sodium's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Divalproex Sodium:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | Virginia Commonwealth University | NA |
RECRUITING
(Apr 1, 2026)
| PHASE1, PHASE2 |